FCX‐146, a potent allosteric inhibitor of Akt kinase in cancer cells: Lead optimization of the second‐generation arylidene indanone scaffold-Reference-Cited by-同舟云学术

FCX‐146, a potent allosteric inhibitor of Akt kinase in cancer cells: Lead optimization of the second‐generation arylidene indanone scaffold

Published:2020-02-24 Issue:1 Volume:68 Page:82-91
ISSN:0885-4513
Container-title:Biotechnology and Applied Biochemistry
language:en
Short-container-title:Biotechnology and Applied Biochemistry

Author:

Balasubramaniam Meenakshisundaram¹,Lakkaniga Naga Rajiv²,Dera Ayed A³⁴^ORCID,Fayi Majed Al³⁴,Abohashrh Mohammed⁵,Ahmad Irfan³⁴,Chandramoorthy Harish C.⁶,Nalini Ganesan⁷,Rajagopalan Prasanna³⁴^ORCID

Affiliation:

1. Department of Geriatrics College of Medicine University of Arkansas for Medical Sciences Little Rock AR USA

2. Department of Pharmaceutical Sciences College of Pharmacy University of Arkansas for Medical Sciences Little Rock AR USA

3. Department of Clinical Laboratory Sciences College of Applied Medical Sciences King Khalid University Abha Saudi Arabia

4. Central Research Laboratory College of Applied Medical Sciences King Khalid University Abha Saudi Arabia

5. Department of Basic Medical Sciences College of Applied Medical Sciences King Khalid University Abha Saudi Arabia

6. Center for Stem Cell Research and Department of Microbiology & Clinical Parasitology College of Medicine King Khalid University Abha Saudi Arabia

7. Department of Chemistry Pachaiyappas College Chennai Tamil Nadu India

Publisher

Wiley

Subject

Process Chemistry and Technology,Drug Discovery,Applied Microbiology and Biotechnology,Biomedical Engineering,Molecular Medicine,General Medicine,Bioengineering,Biotechnology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/bab.1896

Reference35 articles.

1. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes

2. Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?

3. Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer

4. AKT/PKB Signaling: Navigating Downstream

5. AKT/PKB Signaling: Navigating the Network

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SSB-2548 Attenuates C-X-C chemokine receptor type 4 (CXCR-4) Activation to Induce Apoptosis; An in silico Guided invitro Validation in Acute Myeloid Leukemia cells;2023-12-29

2. Revisiting Aurora Kinase B: A promising therapeutic target for cancer therapy;Medicinal Research Reviews;2023-11-20

3. Network pharmacology combined with molecular docking and in vitro verification reveals the therapeutic potential of Delphinium roylei munz constituents on breast carcinoma;Frontiers in Pharmacology;2023-09-01

4. Drug-Delivery Silver Nanoparticles: A New Perspective for Phenindione as an Anticoagulant;Biomedicines;2023-08-04

5. The slow but steady rise of binding free energy calculations in drug discovery;Journal of Computer-Aided Molecular Design;2022-12-05